An interventional study of E-health video in Breast Cancer, Breast Neoplasms and Depression, Anxiety, sponsored by National University of Malaysia. Recruiting at 1 site in Malaysia. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by National University of Malaysia · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Breast Neoplasms with a site in Malaysia — 14 open to participants now, 27 under way, 19 of them phase 3. Breast Neoplasms · Malaysia.
Among the 62 studies in Breast Neoplasms with a site in Malaysia, this one is the 47th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2024, is one of 13 with no phase, reaches primary completion later than 2 of the 26 other live ones, and was the 56th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →14 of the 62 studies in Breast Neoplasms with a site in Malaysia are open now. Recruiting first, the newest first:
BeOne Medicines · Sites in Malaysia, United States, Australia and 13 more countries
Ages 18+
Olema Oncology, Inc. · Sites in Malaysia, United States, Australia and 21 more countries
Ages 18+
Celcuity Inc · Sites in Malaysia, United States, Argentina and 22 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Malaysia, United States, Argentina and 38 more countries
Ages 18+
University of Malaya · Sites in Malaysia
Ages 18+ · Women only
A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 35
First in 1996; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 479 across the 59 interventional studies, 1,151 across the 1 observational. Of the 28 that completed or were terminated, 21 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 62 have an industry lead sponsor. The 10 most frequent:
National University of Malaysia is the lead sponsor of 124 studies on the registry; 42 are open to participants now.
National University of Malaysia has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Breast Neoplasms with a site in Malaysia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
| NCT04862663Phase 3AstraZenecaCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | 2027-11-01 |
| NCT05315700ORIC PharmaceuticalsStudy of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 62 studies in Breast Neoplasms with a site in Malaysia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Purpose: The study aims to assess how effective e-health interventions are at improving mental health help-seeking intentions and behaviours among breast cancer patients.
Intervention: E-health interventions will be utilized to encourage patients to seek mental health support. These interventions are designed to be accessible and convenient, offering support and information through digital platforms.
Participants: The study will involve breast cancer patients between the ages of 18 and 65.
Key Objectives:
Primary Goal: To measure any changes in patients' intentions and actions to seek mental health support before and after using e-health interventions.
Secondary Goals: To explore how these interventions impact mental health literacy, reduce self-stigma, and identify barriers and facilitators to seeking help.
Comparison: The study will compare outcomes for patients using e-health tools against those receiving traditional care without digital interventions.
Expected Outcomes: Researchers anticipate that e-health interventions will improve mental health help-seeking behaviours, enhance understanding of mental health issues, and reduce the stigma associated with seeking support.
Significance: This study could demonstrate the potential of digital health tools to support mental well-being among breast cancer patients, providing new ways to access care and overcome traditional barriers to seeking mental health support.
Study Objective: The study seeks to explore how digital health interventions can enhance the willingness and actions of breast cancer patients to seek mental health support. With the rise of digital technology, there is a growing interest in how these tools can bridge gaps in healthcare access and provide timely support.
Context and Background: Breast cancer patients often face significant emotional and psychological challenges, which can affect their overall well-being and treatment outcomes. Traditional mental health services may not always be accessible due to physical, geographic, or psychological barriers. E-health interventions present an innovative solution by offering support through digital platforms that patients can access from the comfort of their homes.
Digital Interventions: These tools are designed to provide information, support, and motivation, encouraging patients to engage in mental health services.
Methodology:
Participants: The study will recruit breast cancer patients aged 18 to 65, providing a diverse representation of those affected by the condition.
Implementation: Participants will use digital interventions over a specified period, with regular assessments to monitor changes in their mental health help-seeking behaviours and intentions.
Data Collection: Researchers will track metrics such as changes in self-reported mental health literacy, attitudes toward seeking help, self-stigma on seeking help and mental help-seeking intention score.
Comparative Analysis: The study will include a control group receiving standard care without digital interventions to compare outcomes and measure the effectiveness of e-health tools.
Anticipated Benefits:
Accessibility: E-health tools can offer immediate access to resources and support, overcoming barriers such as distance and mobility.
Personalization: Digital platforms can tailor content and support to meet individual needs, enhancing engagement and effectiveness.
Empowerment: By providing information and resources, e-health interventions can empower patients to take proactive steps in managing their mental health.
Significance: The findings from this study could have significant implications for healthcare delivery, demonstrating the value of integrating digital solutions into patient care. Successful implementation of e-health interventions could lead to widespread adoption, improving mental health outcomes for breast cancer patients and potentially other patient groups facing similar challenges.
Conclusion: By leveraging the power of digital technology, this study aims to transform the landscape of mental health support for breast cancer patients, offering new pathways to care that is accessible, effective, and patient-centred.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive the e-health intervention
Other: E-health video
Participants in the control group will receive standard care and Ministry of Health pamphlets without the digital intervention
Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting. Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged. Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere.
Mental Help-Seeking Intention
Help-Seeking Intention: The likelihood or willingness of breast cancer patients to seek professional mental health services. The mental help-seeking intention will be assessed using the Theory of Planned Behaviour (TPB) questionnaires. The help-seeking intention will be measured on a 3-item scale. Responses will be rated on a 6-point Likert scale, with higher scores indicating higher levels of help-seeking intention.
Time frame: baseline, 4 weeks and 12 weeks post intervention
Mental Help-Seeking Behaviour
The actual actions participants took to seek mental health services, such as contacting a mental health professional or accessing online resources. Mental help-seeking behaviour will be assessed by their behaviour of seeking or not seeking help, the answer will be yes or no
Time frame: baseline, 4 weeks and 12 weeks post intervention
Mental Health Literacy
Mental health literacy refers to the knowledge and beliefs about mental disorders that aid in their recognition, management, and prevention. Evaluation: Mental Health Literacy Scale (MHLS)
Time frame: baseline, 4 weeks and 12 weeks post intervention
Attitude of Seeking Help, Subjective Norms, Perceived Behavioural Control (PBC)
Attitude towards help-seeking, subjective norms, as well as PBC, will be assessed using the TPB questionnaires Perceived behavioural control - PBC will be measured on a 3-item scale. Responses will be rated on a 6-point Likert scale, with higher scores indicating higher levels of behavioural control Subjective norms - The subjective norm will be measured on a 3-item scale. Responses will be rated on a 6-point Likert scale, with higher scores indicating higher levels of subjective norm. Attitude towards help-seeking - This aspect will be assessed using 5 items, which will then be evaluated on a 6-point semantic differential scale, where higher scores denote a more favourable attitude towards help-seeking.
Time frame: baseline, 4 weeks and 12 weeks post intervention
Self-stigma of seeking help
Self-stigma refers to the internalized negative perceptions and shame associated with seeking mental health support. Self-stigma in seeking help will be assessed using the Self-Stigma of Seeking Help (SSOSH) questionnaire
Time frame: baseline, 4 weeks and 12 weeks post intervention
Anxiety and Depression
The level of anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS). HADS is a self-reported questionnaire designed to screen anxiety and depressive in a hospital setting
Time frame: baseline, 4 weeks and 12 weeks post intervention
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Sep 2024, 1 month after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 1 month is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University of Malaysia →